Search results for: France

The Life Cycle of Pharmaceuticals: A Cross-National Perspective

1 April 2002

…contribution to the methodology of cross-national comparisons for medicines. In this study we use comprehensive data on outpatient sales for all drugs in seven countries (Canada, France, Germany, Italy, Japan,…

Pharmaceuticals in seven nations

1 May 1985

…pharmaceutical industry, with particular reference to its structure and activities in seven countries – the Federal Republic of Germany, France, Italy, Japan, Switzerland, the United Kingdom and the United States….

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

5 January 2018

…this debate, and of how IBP has been implemented – in its various forms – to date in the U.S., France, Germany, Italy, Spain and the UK. IBP increases the…

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

1 January 2022

…(HTA) agency determines how these challenges are currently addressed. This report provides an analysis of HTA agency assessments and reimbursement decisions for entrectinib and larotrectinib across England, Germany, France, Canada,…

Are Recommendations for HTA of Gene Therapies Being Achieved?

11 September 2023

…develop country scorecards exploring the extent to which these recommendations are being achieved in eleven countries. The countries considered were: Australia, Canada, Denmark, England, France, Germany, Italy, the Netherlands, Spain,…

Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report

18 April 2024

…at the delivery of vaccine programmes in countries that represent a range of healthcare systems, demographics, and vaccine schedules – Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand,…

Value, Affordability, and Decision Making

…March 2026 Around The World in HTAs: France – Three Core HTA Values In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA…

Around the World in HTAs

…and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation. 12 March 2026 Around The World in HTAs: France – Three Core HTA Values In the…

Biosimilars’ Price Dynamic in Europe

30 June 2010

…seminar and summarises the remarks of Dr Matthias Liefner of Simon Kucher and Partners. In Europe, pricing of biosimilars already has begun to affect the market for biologics. For example, France’s compulsory…